Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
26.95
+0.07 (0.26%)
May 20, 2026, 4:00 PM EDT - Market closed
Neurogene Market Cap
Neurogene has a market cap or net worth of $425.86 million as of May 21, 2026. Its market cap has increased by 128.81% in one year.
Market Cap
425.86M
Enterprise Value
191.81M
1-Year Change
128.81%
Ranking
Category
Stock Price
$26.95
Market Cap Chart
Since December 19, 2023, Neurogene's market cap has increased from $193.64M to $425.86M, an increase of 119.93%. That is a compound annual growth rate of 38.51%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| May 20, 2026 | 425.86M | 33.46% |
| Dec 31, 2025 | 319.09M | -6.03% |
| Dec 31, 2024 | 339.58M | 36.64% |
| Dec 29, 2023 | 248.52M | 28.34% |
| Dec 19, 2023 | 193.64M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| 4D Molecular Therapeutics | 442.78M |
| Monopar Therapeutics | 435.09M |
| Autolus Therapeutics | 431.15M |
| Replimune Group | 426.07M |
| PureTech Health | 423.21M |
| Fulcrum Therapeutics | 423.12M |
| Assembly Biosciences | 417.34M |
| Artiva Biotherapeutics | 415.43M |